<DOC>
	<DOCNO>NCT02504983</DOCNO>
	<brief_summary>Transcatheter arterial chemoembolization ( TACE ) + sorafenib therapy demonstrate exert beneficial effective time-to-tumor-progression ( TTP ) patient unresectable hepatocellular carcinoma ( HCC ) study . However , beneficial effect varies among study conduct different area world . The objective study ( 1 ) understand whether GALNT14 TT genotype patient respond good GALNT14 non-TT genotype patient treat TACE ; ( 2 ) understand whether GALNT14 non-TT genotype patient benefit TACE plus sorafenib ( Nexavar ) combination therapy . Patients enrol stratified GALNT14 genotyping . The GALNT14 `` non-TT '' patient randomize two subgroup evaluate safety , tolerability efficacy TACE plus sorafenib therapy . The primary endpoint study efficacy TACE without sorafenib combination therapy evaluate complete remission ( CR ) . The secondary endpoint : 1 . Time partial complete response ( PR + CR ) . 2 . Time-to-tumor-progression ( TTP ) progression free survival ( PFS ) . 3 . Overall survival ( OS ) . 4 . Safety tolerability TACE plus sorafenib therapy .</brief_summary>
	<brief_title>Clinical Trial GALNT14 Genotype - Guided , Sorafenib Combination With TACE Hepatocellular Carcinoma</brief_title>
	<detailed_description>The strategy TACE + sorafenib intensively investigate . It safe approach significant beneficial effect TTP study , beneficial effect OS remain uncertain . In present study , hypothesize GALNT14 genotype might play role issue . Our pilot study indicate GALNT14 `` TT '' genotype associate favorable complete response rate patient treat TACE alone . This genotype present ~ 25 % Chinese population come Taiwan , Colorado ( US ) , Beijing ( China ) , ~ 7 % Italian population . But present ~ 50 % Japanese population . The low percentage TACE - favorable genotype Chinese Italian population could explain different result Japanese Chinese/Italian clinical trial . It possible population high percentage TACE - favorable genotype ( GALNT14 `` TT '' ) , beneficial effect sorafenib adjuvant treatment might detect . In study , propose examine TACE + sorafenib effect patient GALNT14 `` non-TT '' genotype , TACE - unfavorable genotype .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Confirmed Diagnosis HCC : Cirrhotic subject : Clinical diagnosis AASLD criterion HCC define cirrhotic subject one imaging technique ( CT scan , MRI , second generation contrast ultrasound ) show nodule large 2cm contrast uptake arterial phase washout venous late phase , two image technique show radiological behaviour nodule 12cm diameter Cytohistological confirmation require subject fulfill eligibility criterion Noncirrhotic subject : For subject without cirrhosis , histological confirmation mandatory Documentation original biopsy diagnosis acceptable 2 . Never receive TACE/ chemotherapy/ radiotherapy target agent prior study . 3 . Patients either BCLC clinical stage B ( multinodular asymptomatic tumor without extrahepatic spread portal vein invasion ) without unilateral secondary tertiary branch portal vein invasion . Main portal vein invasion extrahepatic spread allow . 4 . ChildPugh functional class A B . 5 . Measurable disease use mRECIST criterion . At least 1 measurable lesion must present . 6 . ECOG performance status 0 1 . 7 . Age &gt; 18 year 8 . Both men woman enrol trial must use adequate birth control measure course trial 4 week completion trial 9 . Informed consent must obtain prior study initiation . 10 . Total bilirubin &lt; 3.0 mg/dL evidence biliary tract obstruction . 11 . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 × upper limit normal . 12 . Absolute neutrophil count &gt; 1000/mm3 ; Platelets ≧ 60x109/L . 13 . Serum creatinine &lt; 2 x ULN . 14 . Antiviral treatment hepatitis B C allow except interferon . 1 . BCLC stage A . 2 . Presence extrahepatic metastasis . 3 . ChildPugh score =C 4 . Significant cardiac disease . 5 . Serious bacteria infection require systemic antibiotic . 6 . Pregnancy 7 . Expected noncompliance . 8 . Uncontrolled illness include , limited , ongoing infection , congestive hear failure , unstable angina pectoris , cardiac arryhythmia , psychiatric illness . 9 . Bleeding esophageal gastric varix within three month without ligation sclerosis injection therapy . 10 . Subjects know HIV infection . 11 . ECOG status &gt; = 2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SNPs</keyword>
</DOC>